# IDEXX Q2 2020 Earnings Highlights (NASDAQ: IDXX)

Reven	ue	Operatin Profit	-	Diluted Earnings Per		
\$638M		\$193M		\$1.72		
Reported growth:	+3%	30% of Revenue				
Organic growth:	+4%	YoY change in basis points:		Reported growth:	+20%	
<b>CAG Diagnostics Recurring</b> Organic Growth: +7%		Reported Constant currency	+380 bps +410 bps	Comparable constant currency growth:	+23%	
CAG	i	<b>d</b> Water		LPD		
Revenue	\$566M	Revenue	\$28M	Revenue	\$32M	
Reported growth:	+ 3%	Reported growth:	-19%	Reported growth:	-3%	
Organic growth:	+ 4%	Organic growth:	-16%	Organic growth:	+2%	
Net CAG Revenue	Q2	Reported Growth Organi	c Growth Q2	Premium Instrument WW	North	

Net CAG Revenue	Q2 Revenue	Growth year over year	Organic Growth year over year	Q2 Premium Instrument Placements	WW	North America	Intl
CAG Diagnostics Recurring	\$510M	+ 7%	+ 7%	Catalyst	1,043	364	679
IDEXX VetLab <sup>®</sup> Consumables	\$196M	+12%	+ 13%	New and competitive	701	165	536
Rapid Assay Products	\$65M	-6%	-5%	Premium Hematology	545	227	318
Reference Laboratory Dx and Consulting Services	\$229M	+ 7%	+ 6%	SediVue <sup>®</sup> Dx	275	182	93
CAG Diagnostics Services and Accessories	\$21M	+ 5%	+ 6%	TOTAL	1,863	773	1,090
CAG Diagnostics Capital – Instruments	\$19M	-40%	-39%				
Veterinary Software, Services and Diagnostic Imaging Systems	\$37M	-4%	-3%				

#### Full Year 2020 Outlook


The company is maintaining suspension of 2020 guidance due to the unpredictability of potential future impacts related to the COVID-19 pandemic.

Impacts of the COVID-19 pandemic have been seen in IDEXX's CAG and Water businesses. Stay-at-home policies deployed to combat the spread of COVID-19 constrained visits to veterinary practices significantly in late March through early April, pressuring diagnostic testing volumes. Restrictions on access of sales professionals to veterinary clinics also contributed to deferrals of new CAG instrument placements. As stay-at-home policies have been relaxed, there has been a significant improvement in clinical visit activity. While these trends are encouraging, potential effects related to ongoing COVID-19 case management efforts and related economic impacts are challenging to predict and may moderate future revenues.

For full financial data, non-GAAP reconciliations and cautionary language regarding forward-looking statements, please refer to IDEXX's 2020 second quarter earnings release issued on July 31, 2020 available at https://www.idexx.com/investors. Amounts presented may not recalculate due to rounding.

IDEXX

## U.S. Companion Animal Practice Growth Update



Total and Clinical Patient Visit Growth



Weighted Average Year-to-Year % Change Per Practice\*

Source: IDEXX Practice Intelligence data; sample of ~7,750 practices representing six different practice information management systems, weighted based on practice size and region to reflect market composition. 'Clinical visits' are those where the reason for visit involves an interaction between a clinician and a pet. \*We estimate net new practice formation adds ~1% of incremental market growth per year beyond per practice growth. Growth rate estimate with margin of error of +/ - 0.4% at a 95% confidence level.

### IDEXX Premium Instruments Installed Base





IDE>

© 2020 IDEXX Laboratories, Inc. All rights reserved. Contact: John Ravis, Investor Relations (207) 556-8155



#### U.S. Average Visits per Practice





#### 2020 Year-Over-Year % Growth Rates

Average per Practice	Q1	Q2	July (3 weeks ending July 17)
Total Practice Revenue	4%	2%	10%
Total Visits	0.3%	-5%	0.3%
Clinical Visits	-0.4%	-3%	6%
Non-Wellness Visits	1%	-1%	2%
Wellness Visits	-3%	-5%	10%

Total visits include clinical and non-clinical visits. In 2019, there were an estimated 315 million U.S. total visits.

Clinical visits are those where the reason for visit involves an interaction between a clinician and a pet. In 2019, there were an estimated 180 million U.S. clinical visits.

Non-wellness visits include those for which the reason for visit is sickness, procedure or monitoring. In 2019, there were an estimated 105 million U.S. non-wellness visits.

Wellness visits include those visits for which the reason for visit is an annual exam, vaccination, or routine check-up. In 2019, there were an estimated 75 million U.S. wellness visits.

Estimated 2019 U.S. companion animal diagnostic market revenue was approximately 75% from non-wellness visits and 25% from wellness visits

#### Week Ended Total Clinical Non-wellness Wellness 3/6 3% 4% 4% 4% 3/13 4% 2% 3% 1% 3/20 3% -9% -5% -15% 3/27 -17% -24% -16% -35% 4/3 -20% -26% -17% -39% 4/10 -20% -25% -16% -36% 4/17 -16% -20% -10% -31% 4/24 -11% -12% -4% -21% 5/1 -8% -8% -2% -15% 5/8 -4% -2% 1% -5% 5/15 -2% 2% 3% 0% 5/22 1% 5% 6% 5% 5/29 1% 7% 5% 8% 6/5 -2% 4% 3% 6% 6/12 1% 7% 5% 9% 6/19 2% 7% 4% 11% 7% 6/26 1% 3% 11% 7/3 -4% 2% -1% 6% 7/10 9% 15% 11% 20% 7/17 -2% 2% -1% 7%

Weekly Year-Over-Year % Growth Rates

\* For both of the weeks ending July 3rd and July 10th, the graph depicts the year-over-year growth estimates for the period of June 27th through July 10th to smooth the volatility related to holiday timing.

Source: IDEXX Practice Intelligence data; sample of ~7,750 practices representing six different practice information management systems, weighted based on practice size and region to reflect market composition. Analysis reflects representative real-time trends on same practice year-over-year growth and does not include adjustments related to equivalent business days and may understate period activity due to latency at clinic level posting daily transactions. We update data for previously reported periods to include subsequent data reporting. Growth rates margin of error of +/ - 0.4% at a 95% confidence level.



## U.S. Companion Animal Market Trends Update As of July 17, 2020

